To the Editor: Because keratinocyte carcinomas (KCs) affect so many people but have a low mortality rate, we investigate their impact on quality of life (QoL). 1 A previous longitudinal study of a high-risk population found minimal effects of new KCs on skin-related QoL. 2 We prospectively analyzed the effect of new KCs to determine if they worsen subsequent skin-related QoL.
We used data from the Veterans Affairs Keratinocyte Carcinoma Chemoprevention Trial (NCT00847912), which followed 932 veterans with multiple KCs treated with topical fluorouracil cream, 5%, or vehicle control for a median of 2.8 years.
3 This research was approved by the Veterans Affairs Central Institutional Review Board; Declaration of Helsinki protocols were followed, and patients gave written, informed consent.
Skindex-29, Skin Cancer Index (SCI), and the Skindex KC-specific subscale were used to measure skin-related QoL at baseline and at 1, 2, and 3 years. 4 Subscale scores were calculated by averaging individual item scores, and total scores of each survey were calculated by averaging the 3 subscales. We performed analyses by using Stata statistical software (release 8.0, StataCorp, College Station, TX). Paired t tests we used to compare participants' skin-related QoL scores at a given time to their own scores 1 year earlier. Unpaired t tests were used to compare the change in skin-related QoL from baseline to year 1 between those with and without new KCs. For year 2 and 3 analyses, multivariable linear regressions accounted for the effect of skin-related QoL and KCs in previous years. All P values are 2-tailed.
Of 932 participants, 815 and 817 completed the Skindex and SCI surveys, respectively, at baseline and year 1. Of those who completed Skindex surveys, 288 developed at least 1 new KC in year 1, 265 in year 2, and 116 in year 3. Development of new KCs was associated with worse skin-related QoL on several subscales in all 3 years (Tables I and II) . Separate analyses of treatment and control groups yielded significant results mostly in the treatment group; however, the interaction term between treatment group and new KC on change in QoL was not statistically significant. 5-fluorouracil use was shown to have no sustained effect on skin-related QoL at 1, 2, or 3 years. 5   Table I . Skindex-29, Skindex KC-specific subscale, and SCI QoL scores in participants with and without development of new KCs from baseline to 1 year Our ability to detect a relationship between skin-related QoL and KCs in longitudinal analyses but not with baseline cross-sectional analyses might indicate the importance of the more precise control of potential confounders that is inherent in comparing each individual to their own prior state.
A strength of this study was our ability to detect change in skin-related QoL by examining the same individuals at different points in time, enabling better control of potential unmeasured confounding factors. Generalizability of findings is limited by the homogenous study population. We cannot confirm the order of events that occurred at the same visit: when surveys were administered and when biopsies were taken. In analyses, we did not account for treatment of KCs during the study.
Our findings of impaired skin-related QoL associated with KCs underscores the importance of appropriate preventative and therapeutic measures; development of new KCs is related to a patient's QoL. 
